References
- Adams JM, Cory S. 2018. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 25: 27-36. https://doi.org/10.1038/cdd.2017.161
- Amodio N, D'Aquila P, Passarino G, Tassone P, Bellizzi D. 2017. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin. Ther. Targets 21: 91-101. https://doi.org/10.1080/14728222.2016.1266339
- Amodio N, Stamato MA, Gulla AM, Morelli E, Romeo E, Raimondi L, et al. 2016. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol. Cancer Ther. 15: 1364-1375. https://doi.org/10.1158/1535-7163.MCT-15-0985-T
- Bong IPN, Ng CC, Baharuddin P, Zakaria Z. 2017. MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy. Genes Genomics 39: 533-540. https://doi.org/10.1007/s13258-017-0518-7
- Botta C, Cuce M, Pitari M, Caracciolo D, Gulla A, Morelli E, et al. 2018. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia 32: 1003-1015. https://doi.org/10.1038/leu.2017.336
- Buschhaus J, Humphries B, Luker K, Luker G. 2018. A Caspase-3 reporter for fluorescence lifetime imaging of single-cell apoptosis. Cells 7: 57. https://doi.org/10.3390/cells7060057
- Chen W, Wang J, Liu S, Wang S, Cheng Y, Zhou W, et al. 2016. MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC. J. Exp. Clin. Cancer Res. 35: 76. https://doi.org/10.1186/s13046-016-0357-4
- Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, et al. 2017. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat. Immunol. 18: 236-245. https://doi.org/10.1038/ni.3654
- Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, et al. 2018. TRAF6 mediates basal activation of NF-κB necessary for hematopoietic stem cell homeostasis. Cell Rep. 22: 1250-1262. https://doi.org/10.1016/j.celrep.2018.01.013
- Gu Y, Xiao X, Yang S. 2017. LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression. Oncotarget 8:101984-101993. https://doi.org/10.18632/oncotarget.21957
- Hu J, Li L, Chen H, Zhang G, Liu H, Kong R, et al. 2018. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Cell Death Dis. 9: 807. https://doi.org/10.1038/s41419-018-0839-8
- Hu Q, Song J, Ding B, Cui Y, Liang J, Han S. 2018. miR-146a promotes cervical cancer cell viability via targeting IRAK1 and TRAF6. Oncol. Rep. 39: 3015-3024.
- Karakas LA, YA Tohma, Kuscu E, Ozen O, Ayhan A. 2019. Analysis of Bcl-2, PTEN, p53, and Ki-67 expressions in endometrial cancer arising from endometrial polyp. Eur. J. Gynaecol. Oncol. 40: 796-802.
- Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, et al. 2017. Inhibition of mitochondrial matrix chaperones and antiapoptotic Bcl-2 family proteins empower antitumor therapeutic responses. Cancer Res. 77: 3513-3526. https://doi.org/10.1158/0008-5472.CAN-16-3424
- Khodadadi-Jamayran A, Akgol-Oksuz B, Afanasyeva Y, Heguy A, Thompson M, Ray K, et al. 2018. Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9: 12868-12878. https://doi.org/10.18632/oncotarget.24403
- Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. 2017. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 15: 230-269. https://doi.org/10.6004/jnccn.2017.0023
- Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, et al. 2017. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat. Commun. 8: 1922. https://doi.org/10.1038/s41467-017-01890-w
- Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, et al. 2016. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut 65: 977-989. https://doi.org/10.1136/gutjnl-2015-309372
- Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, et al. 2017. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell-cycle arrest in colon cancer cells. Cancer Res. 77: 6902-6913. https://doi.org/10.1158/0008-5472.CAN-17-1767
- Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. 2017. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14: 100-113. https://doi.org/10.1038/nrclinonc.2016.122
- Meng YB, He X, Huang YF, Wu QN, Zhou YC, Hao DJ. 2017. Long moncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451. Oncol. Res. 25: 1207-1214. https://doi.org/10.3727/096504017X14886679715637
- Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. 2017. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(suppl 4): iv52-iv61. https://doi.org/10.1093/annonc/mdx096
- Morgan JJ, McAvera RM, Crawford LJ. 2019. TRAF6 Silencing attenuates multiple myeloma cell adhesion to bone marrow stromal cells. Int. J. Mol. Sci. 20: 702. https://doi.org/10.3390/ijms20030702
- Rastgoo N, Abdi J, Hou J, Chang H. 2017. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. J. Hematol. Oncol. 10: 121. https://doi.org/10.1186/s13045-017-0492-1
- Shen X, Zhang Y, Wu X, Guo Y, Shi W, Qi J, et al. 2017. Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark. 18: 257-263. https://doi.org/10.3233/CBM-160158
- Tang L, Zhao B, Zhang H, Du Q, Zhu J, Zhao Z, et al. 2017. Regulation of nonylphenol‐induced reproductive toxicity in mouse spermatogonia cells by miR‐361‐3p. Mol. Rep. Dev. 84: 1257-1270. https://doi.org/10.1002/mrd.22923
- Tassone P, Tagliaferri P, Di Martino MT. Inhibitors of mir-17-92 cluster for anti-tumor activity in multiple myeloma and other malignancies. Google Patents; 2018.
- Tian L, Zhao Z, Xie L, Zhu J. 2018. MiR-361-5p inhibits the mobility of gastric cancer cells through suppressing epithelial-mesenchymal transition via the Wnt/beta-catenin pathway. Gene 675: 102-109. https://doi.org/10.1016/j.gene.2018.06.095
- Xia Y, Chen Y, Tang L, Wang Z, Zheng Y. 2018. Pterostilbene attenuates acute kidney injury in septic mice. Exp. Ther. Med. 15: 3551- 3555.
- Xu Z, Huang C, Hao D. 2017. MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway. Oncol. Rep. 37: 1261-1269. https://doi.org/10.3892/or.2016.5304
- Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, et al. 2016. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 107: 1233-1242. https://doi.org/10.1111/cas.13002
- Zhao D, Cui Z. 2019. MicroRNA-361-3p regulates retinoblastoma cell proliferation and stemness by targeting hedgehog signaling. Exp. Ther. Med. 17: 1154-1162.
- Zhao Y, Cong L, Lukiw WJ. 2018. Plant and Animal microRNAs (miRNAs) and their potential for inter-kingdom communication. Cell Mol. Neurobiol. 38: 133-140. https://doi.org/10.1007/s10571-017-0547-4
- Zhao Y, Xie Z, Lin J, Liu P. 2017. MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met. Am. J. Transl. Res. 9: 2437-2446.